Peter van Vlasselaer
Presidente presso Amphivena Therapeutics, Inc.
Profilo
Peter van Vlasselaer was the founder of Arresto BioSciences, Inc. (founded in 2007) and ARMO BioSciences, Inc. (founded in 2010), where he held the titles of President & Chief Executive Officer and President, Chief Executive Officer & Director, respectively.
He is also the founder of True North Therapeutics, Inc. Dr. van Vlasselaer's current jobs include Independent Executive Chairman at Amphivena Therapeutics, Inc. (since 2019), Director at Inspirna, Inc. (since 2018), and Venture Partner at GSK Equity Investments Ltd.
(since 2021).
Dr. van Vlasselaer's former jobs include President & Chief Executive Officer at Avidia, Inc. (2004-2006), Executive Chairman at Redwood Bioscience, Inc. and iPierian, Inc., Chairman at Asceneuron SA (2019-2023), Independent Chairman at Comet Therapeutics, Inc. (2017-2020), and Director at Blade Therapeutics, Inc. He also held the title of Senior Vice President-Technical Operations at InterMune, Inc. (1999-2004) and Vice President-Drug Development at Dendreon Corp.
(1993-1999).
Dr. van Vlasselaer received his undergraduate and doctorate degrees from Université Catholique de Louvain.
Posizioni attive di Peter van Vlasselaer
| Società | Posizione | Inizio |
|---|---|---|
Inspirna, Inc.
 Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | Direttore/Membro del Consiglio | 27/11/2018 |
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Presidente | 05/03/2019 |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Investitore di Private Equity | 11/02/2021 |
Precedenti posizioni note di Peter van Vlasselaer
| Società | Posizione | Fine |
|---|---|---|
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Presidente | 18/12/2023 |
Comet Therapeutics, Inc.
 Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA. | Presidente | 01/09/2020 |
| ARMO BIOSCIENCES INC | Fondatore | 21/06/2018 |
True North Therapeutics, Inc.
 True North Therapeutics, Inc. BiotechnologyHealth Technology True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA. | Fondatore | 01/05/2017 |
Arresto BioSciences, Inc.
 Arresto BioSciences, Inc. Miscellaneous Commercial ServicesCommercial Services Arresto Biosciences, Inc. is a biotech company that develops medicines to treat cancer and fibrotic diseases by targeting extracellular matrix proteins. The company was founded by Amato Giaccia, Michael T. Longaker and Geoffrey C. Gurtner in 2007 and is headquartered in Palo Alto, California. | Amministratore Delegato | 01/01/2011 |
Formazione di Peter van Vlasselaer
| Université Catholique de Louvain | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 14 |
|---|---|
Avidia, Inc.
 Avidia, Inc. Pharmaceuticals: MajorHealth Technology Avidia, Inc. developed pharmaceutical products. The company developed a novel, proprietary class of small therapeutic proteins. The company was headquartered in Mountain View, CA. | Health Technology |
Arresto BioSciences, Inc.
Arresto BioSciences, Inc. Miscellaneous Commercial ServicesCommercial Services Arresto Biosciences, Inc. is a biotech company that develops medicines to treat cancer and fibrotic diseases by targeting extracellular matrix proteins. The company was founded by Amato Giaccia, Michael T. Longaker and Geoffrey C. Gurtner in 2007 and is headquartered in Palo Alto, California. | Commercial Services |
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
iPierian, Inc.
 iPierian, Inc. Pharmaceuticals: MajorHealth Technology ierian, Inc. developed and manufactured biopharmaceutical products. The firm's lead antibody, IPN007, represents a new approach to treating neurodegenerative disease by targeting a novel form of secreted Tau protein. The company was founded in 2007 and is headquartered in South San Francisco, CA. | Health Technology |
Redwood Bioscience, Inc.
 Redwood Bioscience, Inc. BiotechnologyHealth Technology Redwood Bioscience Inc. develops precision protein-chemical engineering technology to produce the next-generation of antibody-drug conjugates and other semi-synthetic biotherapeutics. It employs natural post translational modifications found in human cells to site specifically create one or more aldehyde tags on protein molecules, including monoclonal antibodies. The firm's platform is enabled with precision chemistries, payload positioning and defined stoichiometry of payload protein ratios. The company was founded by Carolyn R. Bertozzi, Mike Blank and David Rabuka in 2008 and is headquartered in Emeryville, CA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
ARMO BioSciences, Inc.
 ARMO BioSciences, Inc. Pharmaceuticals: MajorHealth Technology ARMO BioSciences, Inc. develops immunotherapy for the treatment of cancer, cardiovascular diseases, fibrosis, and inflammation. Its lead product candidate is AM0010 (pegilodecaki). The company was founded by Peter Van Vlasselaer, Martin Oft, and John B. Mumm on June 23, 2010 and is headquartered in Redwood, CA. | Health Technology |
True North Therapeutics, Inc.
True North Therapeutics, Inc. BiotechnologyHealth Technology True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA. | Health Technology |
Blade Therapeutics, Inc.
 Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Commercial Services |
Comet Therapeutics, Inc.
Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA. | Health Technology |
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | Health Technology |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Health Technology |
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Retail Trade |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Finance |
- Borsa valori
- Insiders
- Peter van Vlasselaer